Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 678 across all filing types
Latest filing 2024-08-26 Investor Presentation
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 90% confidence The document is a letter addressed to stock exchanges notifying them of the schedule for an upcoming analyst/institutional investor meeting. It references compliance with SEBI regulations and provides details of the meeting date and participants. The content is an announcement of a meeting rather than a report or transcript of the meeting itself. The document length is short (1525 characters), and it does not contain financial data, management discussion, or detailed presentation materials. Therefore, it fits best under the category of Investor Presentation (IP) as it relates to investor relations and scheduled meetings with analysts and institutional investors.
2024-08-26 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges notifying them of the schedule of analyst and institutional investor meetings. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, indicating it is a regulatory announcement. The content is about scheduling meetings with investors and analysts, not a financial report, earnings release, or any other detailed report. The document length is short (1715 characters), and it is an announcement rather than a report or transcript. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-08-16 English
Change in Management
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges about a change in senior management personnel, specifically the resignation of the Vice President (Human Resources & Administration). It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulation 30, which pertains to disclosure of material events including management changes. The document includes details about the resignation and the effective date. There is no financial data, no report attached or referenced as published, and no mention of earnings or other financial results. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2024-08-12 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of an earnings conference call for Q1 FY25 of Gland Pharma Limited held on August 6, 2024. It includes management commentary on financial performance, business highlights, segment performance, R&D updates, and a Q&A session. The text contains substantive financial data such as revenue, EBITDA, margins, cash flow, and operational details. The presence of a full transcript of the earnings call with management discussion and Q&A clearly identifies this as a Call Transcript (CT). The document is not merely an announcement or summary but a full transcript of the event.
2024-08-12 English
Copy of Newspaper Publication
Regulatory Filings
2024-08-08 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short letter dated August 8, 2024, addressed to stock exchanges in India, notifying them of the schedule for an upcoming Analyst/Institutional Investor Meeting. It references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs disclosure of material events. The content is purely an announcement of a meeting schedule with no financial data, analysis, or report attached. The document length is only 1532 characters, indicating it is a brief notice rather than a detailed report or presentation. Therefore, this document fits the category of an Investor Presentation announcement or meeting schedule notice. However, since it is only the schedule notification and not the presentation itself, the best fitting category is Regulatory Filings (RNS) as a general regulatory announcement about an investor meeting schedule, not the presentation or report itself.
2024-08-08 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.